Novartis (NVS)’ Ianalumab, for the treatment of primary immune thrombocytopenia, was granted FDA orphan designation, according to a post on the agency’s website. Published first on TheFly ...

Novartis (NVS) has sealed a $3.1 billion deal to acquire clinical-stage biopharmaceutical company Anthos Therapeutics. The ...

Novartis is expanding its prospects in cardiometabolic ... is currently in Phase 3 testing in patients with atrial fibrillation who have a high risk for stroke or systemic embolism.

Swiss pharmaceutical giant Novartis announced on Tuesday the purchase of Cambridge-based biopharma firm Anthos Therapeutics for $925 million upfront. The deal, which is expected to close in the ...

Novartis has set a high bar for any potential obesity-treatment acquisition as it scans the market for deals to fill its drug pipeline and power sales growth into the 2030s, its chief executive said.

Novartis NOVN0.30%increase; green up pointing triangle agreed to acquire Blackstone Life Sciences’ Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline. The deal ...

As for why, exactly, Novartis chose this year and this effort to make its first foray into the high-profile (and high-cost) realm of Super Bowl advertisements, Bulto said the reasons were twofold.

Are you a print subscriber? Activate your account. By Tim Nudd - 19 hours 17 min ago By Amir Farhang - 19 hours 17 min ago By Ashley Joseph - 1 day 17 hours ago By Ad Age Staff - 1 day 17 hours ...

Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive ... of patients globally with atrial fibrillation at high risk of stroke, and we could not have more ...

Novartis is one of the world's top pharmaceutical companies, and along with neighbours Roche, the mainstay of Switzerland's centuries-long contribution to new medicines. Headquartered in Basel ...

Novartis is just months away from filing for ... and swelling that can last for weeks at a time and resist even very high doses of antihistamines, which are the first-line therapy of choice ...

And free cash flow grew 24% to EUR 16.3 billion, a record high for Novartis. Now speaking of ... we think our profile of having very good flare resolution where we showed very compelling data ...